JP2016540051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540051A5 JP2016540051A5 JP2016556693A JP2016556693A JP2016540051A5 JP 2016540051 A5 JP2016540051 A5 JP 2016540051A5 JP 2016556693 A JP2016556693 A JP 2016556693A JP 2016556693 A JP2016556693 A JP 2016556693A JP 2016540051 A5 JP2016540051 A5 JP 2016540051A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- compound according
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 150000001204 N-oxides Chemical class 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 0 C[C@@](*)c1cc(*)ccc1C(N)=* Chemical compound C[C@@](*)c1cc(*)ccc1C(N)=* 0.000 description 13
- SGCNOJRXWAOWPL-UHFFFAOYSA-N CC(C)(C)c(ccc(C)c1)c1F Chemical compound CC(C)(C)c(ccc(C)c1)c1F SGCNOJRXWAOWPL-UHFFFAOYSA-N 0.000 description 2
- OGVXDHCMSPOEMS-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ccc1S(Nc(cc(c(O1)c2)OC1(F)F)c2-c1ccc(C(O)=O)c2c1cccn2)=O Chemical compound CC(C)(C)c(c(F)c1)ccc1S(Nc(cc(c(O1)c2)OC1(F)F)c2-c1ccc(C(O)=O)c2c1cccn2)=O OGVXDHCMSPOEMS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910838P | 2013-12-02 | 2013-12-02 | |
| US61/910,838 | 2013-12-02 | ||
| PCT/US2014/068152 WO2015084842A1 (en) | 2013-12-02 | 2014-12-02 | Ccr6 compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540051A JP2016540051A (ja) | 2016-12-22 |
| JP2016540051A5 true JP2016540051A5 (enExample) | 2018-01-18 |
| JP6563947B2 JP6563947B2 (ja) | 2019-08-21 |
Family
ID=53274030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556693A Active JP6563947B2 (ja) | 2013-12-02 | 2014-12-02 | Ｃｃｒ６化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9340509B2 (enExample) |
| EP (1) | EP3076968B1 (enExample) |
| JP (1) | JP6563947B2 (enExample) |
| KR (1) | KR102331833B1 (enExample) |
| CN (1) | CN105960237B (enExample) |
| AU (1) | AU2014360743C1 (enExample) |
| CA (1) | CA2930148C (enExample) |
| EA (1) | EA029826B1 (enExample) |
| ES (1) | ES2735360T3 (enExample) |
| IL (1) | IL245704B (enExample) |
| MX (1) | MX2016007128A (enExample) |
| WO (1) | WO2015084842A1 (enExample) |
| ZA (1) | ZA201603167B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2735360T3 (es) | 2013-12-02 | 2019-12-18 | Chemocentryx Inc | Compuestos CCR6 |
| KR20200037857A (ko) | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
| IL277071B2 (en) | 2018-03-08 | 2024-07-01 | Incyte Corp | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CA3113805C (en) * | 2018-10-23 | 2023-03-28 | Daiichi Sankyo Company, Limited | Biaryl derivative |
| CN112190708B (zh) * | 2019-07-08 | 2023-09-05 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| EP3996711A4 (en) | 2019-07-10 | 2023-08-16 | ChemoCentryx, Inc. | Indanes as pd-l1 inhibitors |
| KR20220084119A (ko) | 2019-10-16 | 2022-06-21 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아미드 |
| US11866429B2 (en) | 2019-10-16 | 2024-01-09 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| JP2023523300A (ja) | 2020-04-30 | 2023-06-02 | イドーシア ファーマシューティカルズ リミテッド | Ｃｃｒ６受容体調節剤としてのアゼチジン－３－イルメタノール誘導体 |
| WO2023023534A2 (en) * | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
| MX2024002139A (es) | 2021-08-18 | 2024-03-06 | Chemocentryx Inc | Arilsulfonil(hidroxi)piperidinas como inhibidores de ccr6. |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023072924A1 (en) | 2021-10-26 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| TW202325271A (zh) | 2021-10-28 | 2023-07-01 | 瑞士商愛杜西亞製藥有限公司 | Ccr6受體調節劑 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3944553A (en) | 1974-02-13 | 1976-03-16 | Trw Inc. | Bis quinoline peri acids |
| US4021409A (en) | 1975-06-19 | 1977-05-03 | The United States Of America As Represented By The Secretary Of The Air Force | Thermally stable benzimidazonaphthyridine compositions |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| US5833651A (en) | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| EP1748989A2 (en) * | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| ATE503741T1 (de) * | 2005-01-14 | 2011-04-15 | Chemocentryx Inc | Heteroarylsulfonamide und ccr2 |
| WO2008010934A2 (en) * | 2006-07-14 | 2008-01-24 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7683176B2 (en) * | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| WO2009008552A1 (en) | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
| JP5306344B2 (ja) * | 2007-07-12 | 2013-10-02 | ケモセントリックス， インコーポレイテッド | 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド |
| JP2011513196A (ja) * | 2007-08-01 | 2011-04-28 | ハー・ルンドベック・アクチエゼルスカベット | ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用 |
| NZ588511A (en) | 2008-05-23 | 2012-04-27 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| RU2505539C2 (ru) | 2008-12-23 | 2014-01-27 | Эбботт Лэборетриз | Антивирусные соединения |
| SG179085A1 (en) | 2009-09-09 | 2012-04-27 | Avila Therapeutics Inc | Pi3 kinase inhibitors and uses thereof |
| TWI487486B (zh) | 2009-12-01 | 2015-06-11 | Syngenta Participations Ag | 以異唑啉衍生物為主之殺蟲化合物 |
| WO2011119518A1 (en) * | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2012050985A1 (en) | 2010-10-13 | 2012-04-19 | Trustees Of Boston University | Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics |
| KR101985184B1 (ko) | 2011-01-28 | 2019-06-03 | 주식회사 동진쎄미켐 | 신규한 유기염료 및 이의 제조방법 |
| TW201311149A (zh) | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
| EP2747570B1 (en) | 2011-08-25 | 2018-09-19 | Syngenta Participations AG | Isoxazoline derivatives as insecticidal compounds |
| FR2981935B1 (fr) * | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| CA2865714C (en) * | 2012-02-29 | 2021-06-15 | Chemocentryx, Inc. | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
| ES2735360T3 (es) | 2013-12-02 | 2019-12-18 | Chemocentryx Inc | Compuestos CCR6 |
-
2014
- 2014-12-02 ES ES14867718T patent/ES2735360T3/es active Active
- 2014-12-02 US US14/557,949 patent/US9340509B2/en active Active
- 2014-12-02 JP JP2016556693A patent/JP6563947B2/ja active Active
- 2014-12-02 MX MX2016007128A patent/MX2016007128A/es active IP Right Grant
- 2014-12-02 WO PCT/US2014/068152 patent/WO2015084842A1/en not_active Ceased
- 2014-12-02 AU AU2014360743A patent/AU2014360743C1/en active Active
- 2014-12-02 CN CN201480065637.7A patent/CN105960237B/zh active Active
- 2014-12-02 KR KR1020167017459A patent/KR102331833B1/ko active Active
- 2014-12-02 EA EA201691141A patent/EA029826B1/ru not_active IP Right Cessation
- 2014-12-02 EP EP14867718.0A patent/EP3076968B1/en active Active
- 2014-12-02 CA CA2930148A patent/CA2930148C/en active Active
-
2016
- 2016-03-18 US US15/074,965 patent/US9795599B2/en active Active
- 2016-05-11 ZA ZA2016/03167A patent/ZA201603167B/en unknown
- 2016-05-18 IL IL24570416A patent/IL245704B/en active IP Right Grant
-
2017
- 2017-09-19 US US15/709,012 patent/US10117865B2/en active Active
-
2018
- 2018-10-03 US US16/150,796 patent/US10786494B2/en active Active